A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine
Phase of Trial: Phase III
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 28 Aug 2017 Planned End Date changed from 3 Sep 2019 to 23 Dec 2019.
- 28 Aug 2017 Planned primary completion date changed from 6 Nov 2018 to 24 Feb 2019.
- 10 Feb 2017 Status changed from not yet recruiting to recruiting.